Evidence-based Chinese medicine promotes clinical research capacity for emerging infectious diseases_Chinese Journal of Evidence-Based Medicine

Authors：

ZHANG Xinyi ¹ , ZHAO Mengzhu ¹ , LIN Hongyuan ² , YOU Liangzhen ¹ , GUAN Zhiyue ¹ , XU Qianqian ¹ ,  ZHAO Chen ³ ,  SHANG Hongcai ¹

1. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P. R. China;
2. College of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha 410208, P. R. China;
3. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China;

Corresponding?author：

ZHAO Chen, Email: zyyzc2007@163.com; SHANG Hongcai, Email: shanghongcai@126.com

Keywords：

Chinese medicine; Clinical research capacity; COVID-19; Evidence-based medicine

DOI：

10.7507/1672-2531.202302130

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Evidence-based research in traditional Chinese medicine (TCM) has made many important achievements and promoted the modernization and internationalization of TCM. The ability to produce research evidence to guide clinical practice in an emergency treatment situation is a major test of the development of evidence-based Chinese medicine (EBCM) when emerging infectious diseases outbreaks. Along with the development of EBCM, TCM has experienced emerging infectious disease events such as atypical pneumonia (SARS), influenza A (HIN1), and corona virus disease 2019 (COVID-19), and the ability of TCM to conduct clinical research in emergency treatment work has been continuously improved. This article provides an overview of the clinical research conducted in TCM to resist emerging infectious diseases in the past, focusing on the clinical research results obtained in the present time of COVID-19 rescue and treatment, and discusses the role of EBCM development to enhance the clinical research capacity of TCM in emerging infectious diseases.

Citation： ZHANG Xinyi, ZHAO Mengzhu, LIN Hongyuan, YOU Liangzhen, GUAN Zhiyue, XU Qianqian, ZHAO Chen, SHANG Hongcai. Evidence-based Chinese medicine promotes clinical research capacity for emerging infectious diseases. Chinese Journal of Evidence-Based Medicine, 2023, 23(5): 610-615. doi: 10.7507/1672-2531.202302130 Copy

1.	陳可冀, 錢振淮, 張問渠, 等. 精制冠心片雙盲法治療冠心病心絞痛112例療效分析. 中華心血管病雜志, 1982, 10(2): 85-89.
2.	張俊華, 李幼平, 張伯禮. 循證中醫藥學: 理論與實踐. 中國中藥雜志, 2018, 43(1): 1-7.
3.	Tian G, Zhao C, Zhang X, et al. Evidence-based traditional Chinese medicine research: two decades of development, its impact, and breakthrough. J Evid Based Med, 2021, 14(1): 65-74.
4.	王小欽. 正確認識循證醫學. 老年醫學與保健, 2022, 28(2): 221-223.
5.	Song Y, Yao C, Yao Y, et al. Xuebijing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial. Crit Care Med, 2019, 47(9): e735-e743.
6.	Liu Z, Liu Y, Xu H, et al. Effect of electroacupuncture on urinary leakage among women with stress urinary incontinence: a randomized clinical trial. JAMA, 2017, 317(24): 2493-2501.
7.	Xu S, Yu L, Luo X, et al. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. BMJ, 2020, 368: m697.
8.	張俊華, 孫鑫, 李幼平, 等. 循證中醫藥學的現在和未來. 中國循證醫學雜志, 2019, 19(5): 515-520.
9.	中共中央國務院印發《關于促進中醫藥傳承創新發展的意見》. 中醫健康養生, 2019, 5(12): 2.
10.	王眾楷, 張白玉, 賈善群, 等. 2008~2020年中國法定傳染病的流行趨勢分析. 鄭州大學學報(醫學版), 2022, 57(3): 350-356.
11.	潘俊輝, 楊輝, 喻清和, 等. 71例SARS患者中醫藥介入治療的臨床研究. 中國中西醫結合急救雜志, 2003, 10(4): 204-207.
12.	張巍嵐, 王相東, 王郁金, 等. 從國醫大師鄧鐵濤治“非典”經驗探討新型冠狀病毒肺炎中醫診療思路. 中醫學報, 2020, 35(3): 483-486.
13.	International expert meeting on the treatment of SARS by traditional Chinese medicine ATIO. SARS: clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine: report of the WHO international expert meeting to review and analyses clinical reports on combination treatment for SARS. Geneva: World Health Organization, 2004.
14.	Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med, 2011, 155(4): 217-225.
15.	Duan ZP, Jia ZH, Zhang J, et al. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J (Engl), 2011, 124(18): 2925-2933.
16.	戴二黑, 刁士琦, 張洪森, 等. 喜炎平注射液治療2009年甲型H1N1流感回顧性研究. 上海: 中華中醫藥學會兒科分會第二十七屆全國中醫兒科學術研討會暨世界中醫藥學會聯合會第二屆中醫兒科國際學術交流大會、中醫兒科學理論與實踐進展學習班, 2010.
17.	王永炎. 中醫藥防控新型流感作用與體系建設. 北京: 人民衛生出版社, 2015.
18.	商洪才, 張俊華, 戴國華, 等. 中藥大規模臨床試驗及其管理與質量控制. 中西醫結合學報, 2007, 5(1): 1-4.
19.	商洪才, 李幼平, 張伯禮. 中醫藥臨床療效評價實踐中的幾點思考. 天津中醫藥, 2007, 24(4): 275-277.
20.	戴國華, 張伯禮, 郭治昕, 等. 多中心臨床試驗的研究者培訓. 中國新藥雜志, 2007, 16(11): 825-828.
21.	戴國華, 張伯禮, 郭治昕, 等. 大樣本多中心臨床試驗協作單位的選擇. 中國臨床藥理學與治療學, 2006, (6): 717-720.
22.	張俊華, 戴國華, 商洪才, 等. 中醫藥大規模臨床研究的數據核查. 中國循證醫學雜志, 2007, 7(3): 230-232.
23.	張俊華, 商洪才, 戴國華, 等. 實現中醫藥大規模臨床研究的動態管理. 中國中醫藥信息雜志, 2007, (6): 104, 108.
24.	薛素琴, 何羿婷, 盧傳堅, 等. 甲型H1N1流感中醫藥治療臨床研究的質量管理. 重慶醫學, 2011, 40(33): 3249-3250.
25.	戴國華, 張伯禮, 郭治昕, 等. 中心隨機化系統在“芪參益氣滴丸對心肌梗死二級預防的臨床試驗研究”項目中的應用. 中國中西醫結合雜志, 2007, (7): 653-656.
26.	中國臨床試驗注冊中心公告. 中國循證醫學雜志, 2007, 7(8): 557-558.
27.	吳泰相, 李幼平, 卞兆祥, 等. 中醫藥臨床隨機對照試驗報告規范(征求意見稿). 中國循證醫學雜志, 2007, 7(8): 601-605.
28.	劉建平. 循證中醫藥臨床研究方法. 北京: 人民衛生出版社, 2009.
29.	劉云濤, 王進忠, 鄭丹文, 等. 《新型冠狀病毒肺炎診療方案(試行第九版)》中醫藥部分更新解讀. 廣東醫學, 2022, 43(6): 661-663.
30.	李曉東, 劉保延, 王輝, 等. 從治未病談"武昌模式"在突發性急性傳染病防控中的意義. 南京中醫藥大學學報, 2021, 37(1): 1-5.
31.	黃明, 楊豐文, 鄭文科, 等. 中醫藥治療新型冠狀病毒肺炎方艙醫院的建立與成效. 天津中醫藥, 2022, 39(6): 684-687.
32.	何清, 曠吉琳, 陶孟瑤, 等. 新冠肺炎中國臨床研究注冊現狀分析與思考. 中藥與臨床, 2020, 11(5): 1-4,33.
33.	WHO. WHO Expert meeting on evaluation of Traditional Chinese Medicine in the treatment of COVID-19. 2022-05-01.
34.	張曉雨, 趙晨, 孫楊, 等. 推動建立臨床試驗協作與共享機制—疫情蔓延期的戰略思考. 中醫雜志, 2020, 61(8): 650-654.
35.	邱洪全. 多元協同視角下應急科研協同創新機制與動態評價—以重大疫情為例. 科技管理研究, 2021, 41(2): 38-44.
36.	Gong X, Yuan B, Yuan Y, et al. Efficacy and safety of lianhuaqingwen capsules for the prevention of coronavirus disease 2019: a prospective open-label controlled trial. Evid Based Complement Alternat Med, 2021, 2021: 7962630.
37.	An X, Peng B, Huang X, et al. Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med, 2022, 17(1): 42.
38.	史鎖芳, 方祝元, 熊侃, 等. 扶土生金康復方治療COVID-19恢復期肺脾不足證患者臨床觀察. 南京中醫藥大學學報, 2020, 36(3): 281-285.
39.	楊宏志, 林瑞超, 董汛, 等. 香藿噴霧劑聯合基礎康復療法治療新型冠狀病毒肺炎恢復期余毒未清證60例臨床研究. 中醫雜志, 2021, 62(17): 1509-1513.
40.	史鎖芳, 方祝元, 熊侃, 等. 中醫綜合療法治療新型冠狀病毒肺炎恢復期氣陰兩虛證30例臨床研究. 江蘇中醫藥, 2021, 53(1): 25-28.
41.	王輝, 金鑫瑤, 龐博, 等. 中醫藥干預新型冠狀病毒肺炎臨床研究方案分析. 中國中藥雜志, 2020, 45(6): 1232-1241.
42.	李少紅, 王玉光, 何麗云, 等. 新型冠狀病毒肺炎注冊臨床試驗分析及存在的問題與建議. 中醫雜志, 2020, 61(23): 2025-2030.
43.	Qiu R, Zhao C, Liang T, et al. Core outcome set for clinical trials of COVID-19 based on traditional Chinese and Western medicine. Front Pharmacol, 2020, 11: 781.
44.	王月, 陳立, 鄭玲, 等. 清肺排毒湯聯合常規治療對新冠肺炎患者的臨床療效. 中成藥, 2021, 43(3): 656-659.
45.	Wang JB, Wang ZX, Jing J, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med, 2020, 26(9): 648-655.
46.	Luo Z, Chen W, Xiang M, et al. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: a prospective randomized controlled trial. Eur J Integr Med, 2021, 42: 101305.
47.	曾憲紅, 馬文輝, 王潔. 清肺排毒湯對痰熱壅肺型新冠肺炎患者臨床療效的影響. 西部醫學, 2020, 32(12): 1799-1801,1806.
48.	李逸雯, 劉玥, 呂誠, 等. 新型冠狀病毒肺炎的中醫藥臨床研究: 基于文獻計量學分析的解讀與思考. 科學通報, 2021, 66(26): 3385-3394.
49.	Wang Y, Lu C, Li H, et al. efficacy and safety assessment of severe covid-19 patients with chinese medicine: a retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China. J Ethnopharmacol, 2021, 277: 113888.
50.	Zhao C, Li L, Yang W, et al. Chinese medicine formula huashibaidu granule early treatment for mild COVID-19 patients: an unblinded, cluster-randomized clinical trial. Front Med (Lausanne), 2021, 8: 696976.
51.	Liu J, Yang W, Liu Y, et al. Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): a single-center, open-label, randomized controlled trial. Phytomedicine, 2021, 91: 153671.
52.	國家藥監局, 國家衛生健康委. 關于發布藥物臨床試驗質量管理規范的公告. 中華人民共和國國務院公報, 2020, (19): 65-86.
53.	國家衛生和計劃生育委員會. 涉及人的生物醫學研究倫理審查辦法. 中華人民共和國國務院公報, 2017, (27): 44-50.
54.	謝洋, 張彭, 趙虎雷, 等. 國際臨床試驗注冊平臺注冊的新型冠狀病毒肺炎臨床研究特點分析. 中醫雜志, 2020, 61(15): 1294-1298.
55.	胡嘉元, 趙晨, 田然, 等. 中醫藥臨床研究報告規范體系研究. 中國循證醫學雜志, 2018, 18(11): 1151-1157.
56.	Cheng CW, Wu TX, Shang HC, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med, 2017, 167(2): 112-121.
57.	MacPherson H, Altman DG, Hammerschlag R, et al. Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. J Evid Based Med, 2010, 3(3): 140-155.
58.	Fu SF, Cheng CW, Zhang L, et al. Consensus-based recommendations for case report in Chinese medicine (CARC). Chin J Integr Med, 2016, 22(1): 73-79.
59.	劉邁蘭, 劉密, 鐘歡, 等. 新型冠狀病毒肺炎密切接觸隔離人員灸法干預的意義與運行模式研究. 中國針灸, 2020, 40(5): 457-461,471.
60.	凌麗, 呂祥, 孫永寧, 等. 新型冠狀病毒肺炎疫情防控常態化下中醫藥臨床研究實踐與管理的思考. 上海中醫藥雜志, 2022, 56(10): 4-7.
61.	尹永亮, 陳勇, 許梓妮, 等. 新冠肺炎疫情下信息化助力抗腫瘤藥物臨床試驗質量保證. 腫瘤藥學, 2020, 10(S1): 37-41.

1. 陳可冀, 錢振淮, 張問渠, 等. 精制冠心片雙盲法治療冠心病心絞痛112例療效分析. 中華心血管病雜志, 1982, 10(2): 85-89.
2. 張俊華, 李幼平, 張伯禮. 循證中醫藥學: 理論與實踐. 中國中藥雜志, 2018, 43(1): 1-7.
3. Tian G, Zhao C, Zhang X, et al. Evidence-based traditional Chinese medicine research: two decades of development, its impact, and breakthrough. J Evid Based Med, 2021, 14(1): 65-74.
4. 王小欽. 正確認識循證醫學. 老年醫學與保健, 2022, 28(2): 221-223.
5. Song Y, Yao C, Yao Y, et al. Xuebijing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial. Crit Care Med, 2019, 47(9): e735-e743.
6. Liu Z, Liu Y, Xu H, et al. Effect of electroacupuncture on urinary leakage among women with stress urinary incontinence: a randomized clinical trial. JAMA, 2017, 317(24): 2493-2501.
7. Xu S, Yu L, Luo X, et al. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. BMJ, 2020, 368: m697.
8. 張俊華, 孫鑫, 李幼平, 等. 循證中醫藥學的現在和未來. 中國循證醫學雜志, 2019, 19(5): 515-520.
9. 中共中央國務院印發《關于促進中醫藥傳承創新發展的意見》. 中醫健康養生, 2019, 5(12): 2.
10. 王眾楷, 張白玉, 賈善群, 等. 2008~2020年中國法定傳染病的流行趨勢分析. 鄭州大學學報(醫學版), 2022, 57(3): 350-356.
11. 潘俊輝, 楊輝, 喻清和, 等. 71例SARS患者中醫藥介入治療的臨床研究. 中國中西醫結合急救雜志, 2003, 10(4): 204-207.
12. 張巍嵐, 王相東, 王郁金, 等. 從國醫大師鄧鐵濤治“非典”經驗探討新型冠狀病毒肺炎中醫診療思路. 中醫學報, 2020, 35(3): 483-486.
13. International expert meeting on the treatment of SARS by traditional Chinese medicine ATIO. SARS: clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine: report of the WHO international expert meeting to review and analyses clinical reports on combination treatment for SARS. Geneva: World Health Organization, 2004.
14. Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med, 2011, 155(4): 217-225.
15. Duan ZP, Jia ZH, Zhang J, et al. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J (Engl), 2011, 124(18): 2925-2933.
16. 戴二黑, 刁士琦, 張洪森, 等. 喜炎平注射液治療2009年甲型H1N1流感回顧性研究. 上海: 中華中醫藥學會兒科分會第二十七屆全國中醫兒科學術研討會暨世界中醫藥學會聯合會第二屆中醫兒科國際學術交流大會、中醫兒科學理論與實踐進展學習班, 2010.
17. 王永炎. 中醫藥防控新型流感作用與體系建設. 北京: 人民衛生出版社, 2015.
18. 商洪才, 張俊華, 戴國華, 等. 中藥大規模臨床試驗及其管理與質量控制. 中西醫結合學報, 2007, 5(1): 1-4.
19. 商洪才, 李幼平, 張伯禮. 中醫藥臨床療效評價實踐中的幾點思考. 天津中醫藥, 2007, 24(4): 275-277.
20. 戴國華, 張伯禮, 郭治昕, 等. 多中心臨床試驗的研究者培訓. 中國新藥雜志, 2007, 16(11): 825-828.
21. 戴國華, 張伯禮, 郭治昕, 等. 大樣本多中心臨床試驗協作單位的選擇. 中國臨床藥理學與治療學, 2006, (6): 717-720.
22. 張俊華, 戴國華, 商洪才, 等. 中醫藥大規模臨床研究的數據核查. 中國循證醫學雜志, 2007, 7(3): 230-232.
23. 張俊華, 商洪才, 戴國華, 等. 實現中醫藥大規模臨床研究的動態管理. 中國中醫藥信息雜志, 2007, (6): 104, 108.
24. 薛素琴, 何羿婷, 盧傳堅, 等. 甲型H1N1流感中醫藥治療臨床研究的質量管理. 重慶醫學, 2011, 40(33): 3249-3250.
25. 戴國華, 張伯禮, 郭治昕, 等. 中心隨機化系統在“芪參益氣滴丸對心肌梗死二級預防的臨床試驗研究”項目中的應用. 中國中西醫結合雜志, 2007, (7): 653-656.
26. 中國臨床試驗注冊中心公告. 中國循證醫學雜志, 2007, 7(8): 557-558.
27. 吳泰相, 李幼平, 卞兆祥, 等. 中醫藥臨床隨機對照試驗報告規范(征求意見稿). 中國循證醫學雜志, 2007, 7(8): 601-605.
28. 劉建平. 循證中醫藥臨床研究方法. 北京: 人民衛生出版社, 2009.
29. 劉云濤, 王進忠, 鄭丹文, 等. 《新型冠狀病毒肺炎診療方案(試行第九版)》中醫藥部分更新解讀. 廣東醫學, 2022, 43(6): 661-663.
30. 李曉東, 劉保延, 王輝, 等. 從治未病談"武昌模式"在突發性急性傳染病防控中的意義. 南京中醫藥大學學報, 2021, 37(1): 1-5.
31. 黃明, 楊豐文, 鄭文科, 等. 中醫藥治療新型冠狀病毒肺炎方艙醫院的建立與成效. 天津中醫藥, 2022, 39(6): 684-687.
32. 何清, 曠吉琳, 陶孟瑤, 等. 新冠肺炎中國臨床研究注冊現狀分析與思考. 中藥與臨床, 2020, 11(5): 1-4,33.
33. WHO. WHO Expert meeting on evaluation of Traditional Chinese Medicine in the treatment of COVID-19. 2022-05-01.
34. 張曉雨, 趙晨, 孫楊, 等. 推動建立臨床試驗協作與共享機制—疫情蔓延期的戰略思考. 中醫雜志, 2020, 61(8): 650-654.
35. 邱洪全. 多元協同視角下應急科研協同創新機制與動態評價—以重大疫情為例. 科技管理研究, 2021, 41(2): 38-44.
36. Gong X, Yuan B, Yuan Y, et al. Efficacy and safety of lianhuaqingwen capsules for the prevention of coronavirus disease 2019: a prospective open-label controlled trial. Evid Based Complement Alternat Med, 2021, 2021: 7962630.
37. An X, Peng B, Huang X, et al. Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med, 2022, 17(1): 42.
38. 史鎖芳, 方祝元, 熊侃, 等. 扶土生金康復方治療COVID-19恢復期肺脾不足證患者臨床觀察. 南京中醫藥大學學報, 2020, 36(3): 281-285.
39. 楊宏志, 林瑞超, 董汛, 等. 香藿噴霧劑聯合基礎康復療法治療新型冠狀病毒肺炎恢復期余毒未清證60例臨床研究. 中醫雜志, 2021, 62(17): 1509-1513.
40. 史鎖芳, 方祝元, 熊侃, 等. 中醫綜合療法治療新型冠狀病毒肺炎恢復期氣陰兩虛證30例臨床研究. 江蘇中醫藥, 2021, 53(1): 25-28.
41. 王輝, 金鑫瑤, 龐博, 等. 中醫藥干預新型冠狀病毒肺炎臨床研究方案分析. 中國中藥雜志, 2020, 45(6): 1232-1241.
42. 李少紅, 王玉光, 何麗云, 等. 新型冠狀病毒肺炎注冊臨床試驗分析及存在的問題與建議. 中醫雜志, 2020, 61(23): 2025-2030.
43. Qiu R, Zhao C, Liang T, et al. Core outcome set for clinical trials of COVID-19 based on traditional Chinese and Western medicine. Front Pharmacol, 2020, 11: 781.
44. 王月, 陳立, 鄭玲, 等. 清肺排毒湯聯合常規治療對新冠肺炎患者的臨床療效. 中成藥, 2021, 43(3): 656-659.
45. Wang JB, Wang ZX, Jing J, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med, 2020, 26(9): 648-655.
46. Luo Z, Chen W, Xiang M, et al. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: a prospective randomized controlled trial. Eur J Integr Med, 2021, 42: 101305.
47. 曾憲紅, 馬文輝, 王潔. 清肺排毒湯對痰熱壅肺型新冠肺炎患者臨床療效的影響. 西部醫學, 2020, 32(12): 1799-1801,1806.
48. 李逸雯, 劉玥, 呂誠, 等. 新型冠狀病毒肺炎的中醫藥臨床研究: 基于文獻計量學分析的解讀與思考. 科學通報, 2021, 66(26): 3385-3394.
49. Wang Y, Lu C, Li H, et al. efficacy and safety assessment of severe covid-19 patients with chinese medicine: a retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China. J Ethnopharmacol, 2021, 277: 113888.
50. Zhao C, Li L, Yang W, et al. Chinese medicine formula huashibaidu granule early treatment for mild COVID-19 patients: an unblinded, cluster-randomized clinical trial. Front Med (Lausanne), 2021, 8: 696976.
51. Liu J, Yang W, Liu Y, et al. Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): a single-center, open-label, randomized controlled trial. Phytomedicine, 2021, 91: 153671.
52. 國家藥監局, 國家衛生健康委. 關于發布藥物臨床試驗質量管理規范的公告. 中華人民共和國國務院公報, 2020, (19): 65-86.
53. 國家衛生和計劃生育委員會. 涉及人的生物醫學研究倫理審查辦法. 中華人民共和國國務院公報, 2017, (27): 44-50.
54. 謝洋, 張彭, 趙虎雷, 等. 國際臨床試驗注冊平臺注冊的新型冠狀病毒肺炎臨床研究特點分析. 中醫雜志, 2020, 61(15): 1294-1298.
55. 胡嘉元, 趙晨, 田然, 等. 中醫藥臨床研究報告規范體系研究. 中國循證醫學雜志, 2018, 18(11): 1151-1157.
56. Cheng CW, Wu TX, Shang HC, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med, 2017, 167(2): 112-121.
57. MacPherson H, Altman DG, Hammerschlag R, et al. Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. J Evid Based Med, 2010, 3(3): 140-155.
58. Fu SF, Cheng CW, Zhang L, et al. Consensus-based recommendations for case report in Chinese medicine (CARC). Chin J Integr Med, 2016, 22(1): 73-79.
59. 劉邁蘭, 劉密, 鐘歡, 等. 新型冠狀病毒肺炎密切接觸隔離人員灸法干預的意義與運行模式研究. 中國針灸, 2020, 40(5): 457-461,471.
60. 凌麗, 呂祥, 孫永寧, 等. 新型冠狀病毒肺炎疫情防控常態化下中醫藥臨床研究實踐與管理的思考. 上海中醫藥雜志, 2022, 56(10): 4-7.
61. 尹永亮, 陳勇, 許梓妮, 等. 新冠肺炎疫情下信息化助力抗腫瘤藥物臨床試驗質量保證. 腫瘤藥學, 2020, 10(S1): 37-41.

Chinese Journal of Evidence-Based Medicine

Evidence-based Chinese medicine promotes clinical research capacity for emerging infectious diseases

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content